15 completed, 4 active not recruiting, 4 terminated, 3 recruiting. 29 Phase 1, 13 Phase 2.
Follow Recurrent Non-Hodgkin Lymphoma: new trials by email Literature Review of Recurrent Non-Hodgkin Lymphoma trials Research Report on Recurrent Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma Choline Salicylate, Selinexor - Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 22 | 2021-02-08 | 2026-05-28 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2017-01-18 | 2023-02-16 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning - AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2016-06-22 | 2018-12-27 | |
| Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study - Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2015-11-03 | 2022-04-04 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 204 | 2013-05-22 | 2022-05-25 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 71 | 2013-05-16 | 2021-06-24 |
Showing 20 of 29. Sign in to see all of them.
Lymphoma, Non-Hodgkin (29) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Hodgkin Disease (12) · Lymphoma, Mantle-Cell (11) · Lymphoma, Follicular (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, Large B-Cell, Diffuse (7) · Burkitt Lymphoma (6) · Leukemia, Myeloid, Acute (5) · Lymphoma, T-Cell (5) · Multiple Myeloma (5) · Blast Crisis (4) · Lymphoma, T-Cell, Cutaneous (4) · Myelodysplastic Syndromes (4)
Hemic and Lymphatic Diseases (29) · Immune System Diseases (29) · Immunoproliferative Disorders (29) · Lymphatic Diseases (29) · Lymphoma (29) · Lymphoproliferative Disorders (29) · Neoplasms (29) · Neoplasms by Histologic Type (29) · Hematologic Diseases (19) · Chronic Disease (17) · Disease Attributes (17) · Leukemia (17) · Leukemia, Lymphoid (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17)
Cyclophosphamide (8) · CT-P10 (6) · Rituximab (6) · Lenalidomide (5) · Melphalan (5) · Specimen Handling (5) · Nivolumab (4) · fludarabine (4) · fludarabine phosphate (4) · Biopsy (3) · CTLA-4 Antigen (3) · Carmustine (3) · Cytarabine (3) · Etoposide (3) · Ipilimumab (3)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (5) · Fred Hutchinson Cancer Center (4) · Mayo Clinic (3) · City of Hope Medical Center (2) · Ohio State University Comprehensive Cancer Center (2) · AIDS Malignancy Consortium (1) · Children's Oncology Group (1) · OHSU Knight Cancer Institute (1) · Sumithira Vasu (1) · University of Nebraska (1)
United States (29) · Germany (2) · Canada (1) · Italy (1)
Sumithira Vasu, MD (2) · Alexey Danilov (1) · Ariela Noy (1) · Brenda Sandmaier (1) · Chitra Hosing (1) · Crystal L Mackall (1) · David Maloney (1) · Elizabeth L Budde, MD,PhD (1) · Grzegorz S. Nowakowski, M.D. (1) · Hans-Peter Kiem (1) · Jennifer E Amengual (1) · Jin S Im (1) · Jonas Paludo, MD (1) · Jordan Gauthier (1) · Joseph M Tuscano (1)
PMID 34515338, PMID 23834234, PMID 27111235, PMID 27118452, PMID 27410923, PMID 29038338, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31401903, PMID 31617432, PMID 31648294, PMID 32192573, PMID 32478814, PMID 32499241, PMID 32967009, PMID 33720354, PMID 34320785, PMID 34666344, PMID 36631449, PMID 37774014, PMID 39333103, PMID 39863139, PMID 42389828
P30CA015704 (3), P30CA016672 (2), P30CA033572 (2), P50CA097274 (2), P50CA107399 (2), UM1CA186717 (2), N01CM00071 (1), N01CM62201 (1), P01CA078902 (1), P30CA006516 (1), P30CA014599 (1), P30CA016058 (1), P30CA036727 (1), P30CA069533 (1), R01CA136551 (1)